SAEs · people who smoke
It is very uncertain whether longer changes overall SAEs ‐ 26 weeks versus 8 weeks compared with shorter duration of combination nicotine replacement therapy (very low certainty).
3 findings from 1 review
RR 1.63 [0.6, 4.42]
1 study · 544 participants
Very low
no estimate extracted
1 study · 637 participants
Very low
no estimate extracted
1 study · 987 participants
Very low
Treatment withdrawal · people who smoke
1 finding from 1 review
Smoking abstinence at longest · people who smoke
Varenicline leads to higher smoking abstinence at longest compared with placebo or no medication (high certainty).
1 finding from 1 review
SAEs · people who smoke
Cytisine showed no clear difference in SAEs compared with varenicline (low certainty).
1 finding from 1 review
Neuropsychiatric SAEs · people who smoke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiac SAEs · people who smoke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Smoking abstinence at longest · people who smoke
Varenicline leads to higher smoking abstinence at longest compared with bupropion (high certainty).
1 finding from 1 review
SAEs · people who smoke
Varenicline showed no clear difference in SAEs compared with bupropion (low certainty).
1 finding from 1 review
Neuropsychiatric SAEs · people who smoke
Varenicline showed no clear difference in neuropsychiatric SAEs compared with bupropion (low certainty).
1 finding from 1 review
SAEs · people who smoke
Varenicline probably leads to higher SAEs (varenicline vs placebo or no medication) compared with placebo or no medication (moderate certainty).
1 finding from 1 review
Cardiac SAEs · people who smoke
Varenicline showed no clear difference in cardiac SAEs compared with bupropion (low certainty).
1 finding from 1 review
Smoking abstinence at longest · people who continued to smoke tobacco following acute coronary syndrome
It is very uncertain whether varenicline changes smoking abstinence at longest compared with e‐cigarettes (very low certainty).
1 finding from 1 review
Neuropsychiatric SAEs · people who smoke
Varenicline showed no clear difference in neuropsychiatric SAEs (varenicline vs placebo or no medication) compared with placebo or no medication (low certainty).
1 finding from 1 review
SAEs · people who continued to smoke tobacco following acute coronary syndrome
1 finding from 1 review
Neuropsychiatric SAEs · people who continued to smoke tobacco following acute coronary syndrome
1 finding from 1 review
Cardiac SAEs · people who continued to smoke tobacco following acute coronary syndrome
1 finding from 1 review
Cardiac SAEs · people who smoke
Varenicline showed no clear difference in cardiac SAEs (varenicline vs placebo or no medication) compared with placebo or no medication (low certainty).
1 finding from 1 review
Smoking abstinence at longest · people who smoke
Cytisine probably leads to higher smoking abstinence at longest compared with placebo or no medication (moderate certainty).
1 finding from 1 review
SAEs · people who smoke
Cytisine showed no clear difference in SAEs (cytisine vs placebo or no medication) compared with placebo or no medication (low certainty).
1 finding from 1 review
Neuropsychiatric SAEs · people who smoke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found